Consun Pharmaceutical Group (SEHK:1681) Earnings Growth And 31.5% Margins Challenge Valuation Skeptics

Simply Wall St.03-28

Consun Pharmaceutical Group (SEHK:1681) opened FY 2025 with first half revenue of C¥1.57b and basic EPS of C¥0.59, set against trailing twelve month revenue of C¥3.42b and EPS of C¥1.27 that reflect ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622384552?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-03-28 20:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622384552","market":"us","top_or_hot":-1,"title":"Consun Pharmaceutical Group (SEHK:1681) Earnings Growth And 31.5% Margins Challenge Valuation Skeptics","media":"Simply Wall St.","content":"<div>\n<p>Consun Pharmaceutical Group (SEHK:1681) opened FY 2025 with first half revenue of C¥1.57b and basic EPS of C¥0.59, set against trailing twelve month revenue of C¥3.42b and EPS of C¥1.27 that reflect ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1681/consun-pharmaceutical-group-shares/news/consun-pharmaceutical-group-sehk1681-earnings-growth-and-315\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Consun Pharmaceutical Group (SEHK:1681) Earnings Growth And 31.5% Margins Challenge Valuation Skeptics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nConsun Pharmaceutical Group (SEHK:1681) Earnings Growth And 31.5% Margins Challenge Valuation Skeptics\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-28 20:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1681/consun-pharmaceutical-group-shares/news/consun-pharmaceutical-group-sehk1681-earnings-growth-and-315><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Consun Pharmaceutical Group (SEHK:1681) opened FY 2025 with first half revenue of C¥1.57b and basic EPS of C¥0.59, set against trailing twelve month revenue of C¥3.42b and EPS of C¥1.27 that reflect ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1681/consun-pharmaceutical-group-shares/news/consun-pharmaceutical-group-sehk1681-earnings-growth-and-315\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1681/consun-pharmaceutical-group-shares/news/consun-pharmaceutical-group-sehk1681-earnings-growth-and-315","article_id":"2622384552","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1681/consun-pharmaceutical-group-shares/news/consun-pharmaceutical-group-sehk1681-earnings-growth-and-315","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622384552","pubTimestamp":1774699865,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Consun Pharmaceutical Group (SEHK:1681) opened FY 2025 with first half revenue of C¥1.57b and basic EPS of C¥0.59, set against trailing twelve month revenue of C¥3.42b and EPS of C¥1.27 that reflect earnings growth of 18.4% over the past year. The company has seen revenue move from C¥2.97b to C¥3.42b on a trailing basis, while EPS has gone from C¥1.11 to C¥1.27, supported by a trailing net profit margin of 31.5% that edges above last year’s 30.7%. This keeps profitability squarely in focus...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","01681":"康臣药业","BK1606":"中医药概念"},"translate_title":"康臣药业集团（SEHK：1681）盈利增长和31.5%利润率挑战估值怀疑论者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01681":0.9},"content_text":"Consun Pharmaceutical Group (SEHK:1681) opened FY 2025 with first half revenue of C¥1.57b and basic EPS of C¥0.59, set against trailing twelve month revenue of C¥3.42b and EPS of C¥1.27 that reflect earnings growth of 18.4% over the past year. The company has seen revenue move from C¥2.97b to C¥3.42b on a trailing basis, while EPS has gone from C¥1.11 to C¥1.27, supported by a trailing net profit margin of 31.5% that edges above last year’s 30.7%. This keeps profitability squarely in focus for investors weighing the latest release. See our full analysis for Consun Pharmaceutical Group. With the headline numbers on the table, the next step is to see how this earnings profile lines up with the prevailing narratives around Consun Pharmaceutical Group and where those stories might need a rethink. Curious how numbers become stories that shape markets? Explore Community Narratives SEHK:1681 Earnings & Revenue History as at Mar 2026 Advertisement18.4% earnings growth meets 31.5% margins  Over the last 12 months, net income reached C¥1,078.1m with earnings growth of 18.4% and a trailing net profit margin of 31.5%, compared with 30.7% a year earlier. What stands out for a bullish view is that solid profitability lines up with multi year earnings compounding of about 15% per year, while:\n     First half FY 2025 net income of C¥498.3m already sits close to the C¥510.7m reported in the prior half, keeping the trailing C¥1,078.1m total well supported. Trailing EPS of C¥1.27 compares with C¥0.59 in the latest half year, so the current run rate is framed by a longer period of higher earnings rather than a single strong half.    Revenue growth forecasts around 11.7% a year  Revenue is forecast to grow about 11.7% per year, while earnings are forecast to grow around 12% per year, both measured against the trailing base of C¥3,417.4m in revenue and C¥1,078.1m in net income. Supporters of a bullish angle point to these growth rates as a continuation of the recent 18.4% earnings growth, yet the numbers also invite a closer look:\n     Recent semi annual revenue of C¥1,568.6m for FY 2025 first half and C¥1,698.7m for FY 2024 second half show the business operating around the C¥1.6b to C¥1.7b range per half, which is consistent with the current trailing C¥3.4b level. The move in basic EPS from C¥0.50 in FY 2024 first half to C¥0.59 in FY 2025 first half sits alongside the multi year growth profile, so the forecasts are being compared to an earnings base that has already expanded.    P/E of 12x versus DCF fair value at HK$29.52  The shares trade on a P/E of 12x, slightly above the Hong Kong pharmaceuticals industry average of 11.1x and well below a peer average of 29.8x, while a DCF fair value of HK$29.52 sits above the current share price of HK$17.39. Critics highlight that the stock is not clearly cheap versus the immediate industry, yet the valuation data also show areas that support a more optimistic reading:\n     The 12x P/E, only modestly above the 11.1x industry level, sits beside an 18.4% earnings growth rate and 31.5% margin, which some bullish investors view as strong quality metrics for that multiple. The DCF fair value of HK$29.52 compared with the HK$17.39 share price implies a large gap to that model, even as the unstable dividend track record gives income focused investors a specific point to question.    If you want to see how other investors are connecting these growth, margin and valuation figures into a bigger picture story, it is worth checking the wider community views on Consun Pharmaceutical Group Curious how numbers become stories that shape markets? Explore Community Narratives Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Consun Pharmaceutical Group's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. The mix of growth, margins and valuation can look either reassuring or concerning depending on what matters most to you. Take a moment to review the numbers, weigh both the potential downsides and upsides, and then check the 3 key rewards and 1 important warning sign. See What Else Is Out There Consun Pharmaceutical Group pairs strong margins with an unstable dividend record and a valuation that some readers may find unconvincing against closer peers. If that mix leaves you wanting more dependable income and pricing, it is worth scanning companies in the 470 dividend fortresses while this earnings season is fresh in mind.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622384552","isCrawlerRequest":true}